Skip to content

Identification of Liver Tumours Using BIP - Biopsy System

INJ-LIVERB-01 Identification of Liver Tumours Using BIP - Biopsy System

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02620228
Enrollment
26
Registered
2015-12-02
Start date
2016-06-09
Completion date
2018-11-30
Last updated
2018-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Biopsy

Keywords

Bioimpedance, Biopsy, Liver tumour, Biopsy needle guidance

Brief summary

This clinical device investigation is conducted by performing liver biopsies using the BIP - Biopsy Tool. The aim is to assess the feasibility of bioimpedance spectroscopy based biopsy tool guidance method and test how well BIP biopsy system is able to distinguish liver tumours from surrounding tissue. In addition, user feedback is obtained to improve the usability of the investigational device. The study does not affect the traditional treatment procedure and only the patients in clinical need for diagnosis by liver biopsy are included on voluntary basis. The invasive products used in actual biopsy operation are designed so that their performance is essentially equal to the currently used biopsy devices, the only difference is the measurement capability of biopsy needle and connection to measurement device.

Interventions

DEVICEBIP Biopsy System

BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.

Sponsors

Injeq Ltd
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Consenting adults undergoing ultrasound-guided core liver biopsy to diagnose liver tumour or other abnormalities * Identifiable non-tumorous liver tissue along the planned needle injection path.

Exclusion criteria

* Inability to give informed consent * Being under aged * Being pregnant * Being high risk patient * Lack of identifiable non-tumorous liver tissue along the injection path to the tumour location * Known contraindications to liver biopsy.

Design outcomes

Primary

MeasureTime frameDescription
Difference in mean between measured bioimpedance spectra from tumorous and nontumorous tissueDuring liver biopsy (couple of minutes/patient)Liver biopsy is performed in traditional way but with biopsy needle that enables bioimpedance measurement from multiple frequencies (spectrum). Tumorous and nontumorous tissue is measured during ultrasound guided biopsy procedure and the tumorous tissue type is verified by histological biopsy sample analysis. The bioimpedance spectra (impedance and phase angle) are compared with each other and differences in means of the spectra calculated. The data analysis is performed offline.

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026